A Phase 4 interventional study of Levobupivacaine and Ropivacaine in Pain and Arthroplasty, Replacement, Knee, sponsored by NHS Tayside. Terminated. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-05-09.
Sponsored by NHS Tayside · Phase 4, Interventional, and Treatment
The anaesthetic management of patients undergoing total knee replacement is still not standardised. Epidural analgesia is common, but is associated with bilateral lower limb motor block and limited mobilisation. Spinal anaesthesia with intrathecal morphine provides good pain relief, but only for 12 to 16 hours, and is often associated with nausea and vomiting. Combined single injection femoral / sciatic blocks give good pain relief, but for a variable length of time (between 12 and 24 hours).
In contrast, continuous femoral perineural infusion of local anaesthetic provides very good pain relief for several days. Pain relief is maintained by a constant infusion of local anaesthetic using an elastomeric ball. The investigators overriding aim is to develop a local anaesthetic regimen which offers complete pain relief for at least 48 hours, yet allows full mobilisation within 24 hours Given that ropivacaine may offer a more advantageous pharmacological profile (less lipid solubility) compared to levobupivacaine, the investigators feel it is pertinent to investigate the capacity of ropivacaine to prevent pain relief after surgery. Thus, the investigators aim in this study is to compare the median effective dose of levobupivacaine with the of ropivacaine for preventive pain relief after total knee replacement. Further, calculation of the equipotent median effective dose's of each local anaesthetic allied to objective measurement of quadriceps motor block using an electromyogram will allow us to determine the sensory - motor split of each local anaesthetic.
Primary objective The primary aim of this study is to measure the molar of levobupivacaine and the molar median effective dose of ropivacaine when administered as a femoral perineural infusion to prevent pain 30 hours after total knee replacement Secondary objectives
To assess the:
Degree of postoperative pain, need for rescue analgesia,side effect profile of both groups, self-efficacy, expectancy, quality of life / health economics Type of study: Prospective single blind randomised controlled trial Planned number of subjects: 48 Study duration: 24 months Randomisation procedures Following informed consent, participants will be randomised into two groups. All preparations for study will be coded so that participants have an equal chance of receiving one of the two local anesthetics. Randomisation will be carried out by computer program, and codes kept in pharmacy in a sealed envelope.
Protocol for patient management Preoperative - Anaesthetic room Antibiotics: augmentin 1.2 grams Sedation with Target Controlled Infusion of propofol at plasma level of 0.5 micrograms per millilitre (μg.ml-1) Spinal anaesthesia with 3.2 ml hypobaric "plain" bupivacaine 0.5% and intrathecal morphine 0.1 mg All regional nerve blocks performed under ultrasound control Femoral block: 15 ml 0.3% levobupivacaine or ropivacaineFemoral perineural catheter inserted by Anaesthetist 5cm in a cranial direction Sciatic block: single injection 12 ml 0.5% levobupivacaine or ropivacaine Obturator block: single injection 6 ml 0.5% levobupivacaine or ropivacaine
Postoperative 8 hour anaesthetic observation
Determine median effective dose of levobupivacaine and ropivacaine for anaesthesia 8 hours after insertion of spinal needle, resolution of spinal anaesthesia confirmed and verbal rating pain score of knee bending recorded. Clinical measurement and subsequent patient dosing is as follows:
After the 8 hour assessment, all patients (excluding technical failures but including "anaesthetic failures") will start a femoral perineural infusion with levobupivacaine or ropivacaine at a rate of 10ml h-1 and concentration of 1(microMolar per millilitre) μM.ml-1 (400μM in 400ml elastomeric ball) for 48 hours.Patients classed as "technical failure" will have a femoral perineural catheter reinserted.
Postoperative 30 hour (±2hour) anaesthetic observation
The postoperative 30 hour anaesthetic observation will only be performed on the "anaesthetic successes" from the 8 hour observation. The median effective dose of levobupivacaine and ropivacaine for analgesia will be determined by choosing an end point of verbal rating pain score 0 at 30h after the start of spinal anaesthesia. Patients will divide into three groups:
Rescue analgesia Rescue will be standardised: 15ml, 50μM levobupivacaine (5.8ml, 0.25% + saline) or 15ml, 50μM ropivacaine (7.7ml, 0.20% + saline). The number of rescue administrations will be counted.
.
NHS Tayside is the lead sponsor of 28 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Local anaesthetic bolus and infusion
Drug: Levobupivacaine
Local anaesthetic bolus and infusion
Drug: Ropivacaine
Femoral bolus 150μM followed by femoral infusion 400μM
Also known as: Chirocaine
Bolus and infusion
Also known as: Naropin
Pain
Number achieving pain on movement of knee measured as 0 on a verbal pain rating scale at 30h after start of perineural infusion
Time frame: 30 hours
Patients recruited on ward 24h before procedure. Patient information sheet sent to patients 3 weeks before operation
| Milestone | Ropivacaine | Levobupivacaine |
|---|---|---|
| Started | 7 | 7 |
| Completed | 7 | 7 |
| Not completed | 0 | 0 |
Number achieving pain on movement of knee measured as 0 on a verbal pain rating scale at 30h after start of perineural infusion
| Participants | Ropivacaine | Levobupivacaine |
|---|---|---|
| Pain | 7 | 7 |
Collected over 30h. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ropivacaine | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
| Levobupivacaine | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
| Age, Continuous(years) | Ropivacaine | Levobupivacaine | Total |
|---|---|---|---|
| Median | 60 (53 to 70) | 64 (56 to 72) | 62 (53 to 72) |
| Sex: Female, Male(Participants) | Ropivacaine | Levobupivacaine | Total |
|---|---|---|---|
| Female | 3 | 2 | 5 |
| Male | 4 | 5 | 9 |
| Race and Ethnicity Not Collected(Participants) | Ropivacaine | Levobupivacaine | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Ropivacaine | Levobupivacaine | Total |
|---|---|---|---|
| United Kingdom | 7 | 7 | 14 |
No study locations are listed for this record.
This study is terminated, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NHS Tayside